Back to top

Opus Genetics enrolls last patient in OPGx-LCA5 trial

Opus Genetics (IRD) announced that the last patient has been enrolled in its registrational Phase 3 clinical trial evaluating OPGx-LCA5, the compan...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Opus Genetics, Inc. (IRD)